tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kyverna Therapeutics price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kyverna Therapeutics (KYTX) to $10 from $5 and keeps a Buy rating on the shares. The firm says the company’s key opinion leader event provided a key disclosure that all three compassionate-use myasthenia gravis patients treated with KYV-101 remain in drug-free, disease-free remission, with follow-up now at 24 months, 22 months, and 15 months, respectively. The data strengthens H.C. Wainwright’s conviction in KYV-101’s long-term prospects.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1